Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

BACKGROUND: CALGB 100104 (Alliance) studied lenalidomide vs. placebo following autologous stem cell transplant (ASCT) for newly diagnosed myeloma patients, demonstrating improved time to progression (TTP) and overall survival (OS), and an increase in second primary malignancies (SPM) for lenalidomid...

Descripción completa

Detalles Bibliográficos
Autores principales: Holstein, Sarah A., Jung, Sin-Ho, Richardson, Paul G., Hofmeister, Craig C., Hurd, David D., Hassoun, Hani, Giralt, Sergio, Stadtmauer, Edward A., Weisdorf, Daniel J., Vij, Ravi, Moreb, Jan S., Callander, Natalie S., van Besien, Koen, Gentile, Teresa G., Isola, Luis, Maziarz, Richard T, Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H, Rodriguez, Cesar, McClune, Brian, Schlossman, Robert L., Smith, Scott E., Hars, Vera, Owzar, Kouros, Jiang, Chen, Boyd, Molly, Schultz, Chelsea, Wilson, Marcia, Hari, Parameswaran, Pasquini, Marcelo C., Horowitz, Mary M., Shea, Thomas C., Devine, Steven M., Linker, Charles, Anderson, Kenneth C., McCarthy, Philip L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718627/
https://www.ncbi.nlm.nih.gov/pubmed/28826616
http://dx.doi.org/10.1016/S2352-3026(17)30140-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718627/
https://www.ncbi.nlm.nih.gov/pubmed/28826616
http://dx.doi.org/10.1016/S2352-3026(17)30140-0

Ejemplares similares